Oncology

Background Identifying molecular alterations specific to advanced lung adenocarcinomas could provide insights into tumour progression and disseminatio...

First-line durvalumab (Imfinzi) plus etoposide and either carboplatin or cisplatin (EP) produced a significant improvement in overall survival (OS) co...

The FDA has approved selumetinib (Koselugo) granules and capsules for the treatment of pediatric patients who are 1 or older with neurofibromatosis ty...

Interim results from the phase 2 pivotal portion of the phase 1/2 PYNNACLE trial (NCT04585750) demonstrated that rezatapopt (PC14586) was efficacious...

The FDA has accepted a new drug application (NDA) for relacorilant (CORT125134) as a treatment for patients with platinum-resistant ovarian cancer, ac...

At the Society of Hematological Oncology 2025 Annual Meeting, CancerNetwork® spoke with Sundar Jagannath, MBBS, about his presentation on potentially...

Tarlatamab-dlle (Imdelltra) plus an anti-PD-1 therapy retained long-term durability in the first-line for patients with extensive-stage small cell lun...

The incidence of oral cavity cancers (OCC) in the UK is rising. In England, oral cancer rates, including cancers of the oral cavity and oropharynx, ha...

Recent data presented at a major oncology conference examined the clinical utility of circulating tumor DNA (ctDNA) monitoring combined with standard...

Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be...